| I-016 Giammarco Baiardi population pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation Wednesday 10:20-11:50 |
| I-045 Nils Bundgaard Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD) Wednesday 10:20-11:50 |
| I-046 Andrew Butler Predicting the effect of postpartum changes in breastmilk composition on the partitioning of anti-malarial medications Wednesday 10:20-11:50 |
| I-070 Craig Comisar Population pharmacokinetic modeling to support dose selection of zavegepant nasal spray in pediatrics. Wednesday 10:20-11:50 |
| I-075 Liu Dan Population pharmacokinetics modeling of selpercatinib and simulation to support posology in paediatric and adolescent patients Wednesday 10:20-11:50 |
| I-086 Laure Deyme Population pharmacokinetic analysis of eliglustat in pediatric patients with Gaucher disease Wednesday 10:20-11:50 |
| I-115 Gastón García Orueta Population pharmacokinetics of teicoplanin in critically ill children undergoing continuous kindey replacement therapy Wednesday 10:20-11:50 |
| II-012 Katharina Martha Götz The dose-response relationship of rituximab in pediatric patients after allogeneic hematopoietic stem cell transplantation – Model-informed evidence generation for a real-world problem Wednesday 15:20-16:50 |
| II-022 Andrea Guzmán Potential of Tacrolimus CYP3A5 genotyping to predict phenotype (C0/Dose/Weight ratio) and applicability of PBPK modelling to improve dosing strategies in paediatric kidney transplant recipients Wednesday 15:20-16:50 |
| II-030 Huan He Is the model predictive performance with von Willebrand factor superior to others? An external evaluation of population pharmacokinetic models for FVIII concentrate BAY 81-8973 in pediatric patients with haemophilia A Wednesday 15:20-16:50 |
| II-091 Sebastiano Lava Study design optimization in paediatric rare diseases: a case study on empagliflozin in paediatric heart failure Wednesday 15:20-16:50 |
| II-108 CHENYAO LIU Population Pharmacokinetic of ketamine and norketamine in pediatric subjects during analgosedation Wednesday 15:20-16:50 |
| III-018 Andres Mazariegos Herrera Weight-band based simplification of oral allometric miltefosine dosing in pediatric patients with visceral leishmaniasis in Eastern Africa Thursday 09:50-11:20 |
| III-057 Zinnia Parra-Guillen Optimal study design for pharmacokinetic modeling of teicoplanin in critically ill children, including those undergoing Continuous Renal Replacement Therapy Thursday 09:50-11:20 |
| III-077 Laure-Hélčne Préta Antidepressants transplacental transfer modeling using ex vivo perfusion of isolated human placenta cotyledon Thursday 09:50-11:20 |
| IV-001 Gianluca Selvaggio Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children Thursday 15:00-16:30 |
| IV-046 Lufina Tsirizani Population pharmacokinetics of ritonavir administered to boost lopinavir, atazanavir, or darunavir in children with HIV in Africa. Thursday 15:00-16:30 |
| IV-055 Jennie van Dyk Oral amoxicillin/clavulanate in paediatric patients with severe community acquired pneumonia: a popPK analysis from the PediCAP trial Thursday 15:00-16:30 |
| IV-059 Anne van Rongen The impact of being born Small for Gestational Age (SGA) on the clearance of vancomycin versus morphine and midazolam Thursday 15:00-16:30 |
| IV-093 Jen-Hao (Eric) Wu Clinical trial design evaluation in pediatric oncology: Phase I dose finding trial design optimization exemplified by brigatinib (ITCC-098) Thursday 15:00-16:30 |
| IV-095 Maria Xiberras External Validation of a Population Pharmacokinetic Model for Morphine and its Metabolites in Children under 3 Years who Underwent Cardiothoracic Surgery Thursday 15:00-16:30 |
| IV-111 Qiaolin Zhao Population pharmacokinetic analysis for pediatric patients with inflammatory bowel disease receiving infliximab Thursday 15:00-16:30 |
| IV-115 Yuanxi Zou Pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistance tuberculosis Thursday 15:00-16:30 |
